BioAssay Plus

Executive Summary

BioAssay Plus, founded in 2018 and headquartered in Chicago, is a private platform-stage company offering comprehensive bioassay development and validation services for the pharmaceutical and biotechnology sectors. With a team of 10–50 employees, the company covers diagnostics, biologics, and small molecules, serving as a critical partner in drug discovery and development. Despite limited public information and no disclosed funding or revenue, the company's focus on high-quality bioassay services positions it within a growing market driven by increasing R&D outsourcing and complex therapeutic modalities. The absence of commercial products or FDA approvals suggests an early stage, but its service-based model may provide stable recurring revenue if client engagements are secured. BioAssay Plus operates in a fragmented but expanding bioassay services market, where demand is fueled by the rise of biologics and personalized medicine. The company's ability to support multiple modalities (small molecules, biologics, diagnostics) offers diversification, though competition from larger CROs like Charles River and LabCorp is intense. Given its private nature and lack of disclosed milestones, conviction in near-term value creation is moderate. Key catalysts would include announcing strategic collaborations, expanding service capacity, or securing regulatory certifications. The company's estimated valuation and lean profile suggest it may be a niche player seeking steady growth rather than exponential disruption.

Upcoming Catalysts (preview)

• Q4 2026Strategic partnership with mid-tier pharma for integrated bioassay services40% success
• Q1 2027Launch of novel cell-based assay validation service leveraging AI35% success
• TBDExpansion into European or Asian markets via new lab facilities30% success